Recombinant Human Erythropoietin/EPO Protein (RPCB0903)
- SKU:
- RPCB0903
- Size:
- 10µg
- Tag:
- C-hFc
- Reactivity:
- Human
- Expression Host:
- HEK293 cells
Description
| Product Name: | Recombinant Human Erythropoietin/EPO Protein |
| SKU: | RPCB0903 |
| Size: | 10µg |
| Tag: | C-hFc |
| Reactivity: | Human |
| Expression Host: | HEK293 cells |
| Protein Description: | High quality, high purity and low endotoxin recombinant Recombinant Human Erythropoietin/EPO Protein , tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed. |
| Endotoxin: | <0.1EU/μg |
| Purity: | > 95% by SDS-PAGE. |
| Formulation: | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
| Gene ID: | 2056 |
Human Erythropoietin (EPO) is also known as EP, erythropoetin or erthropoyetin, and is a glycoprotein hormone that controls erythropoiesis, or red blood cell production.It has neuroprotective activity against a variety of potential brain injuries and antiapoptotic functions in several tissue types. Erythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. It is produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. It has a longer circulating half-life in vivo. Erythropoietin is being much misused as a performance-enhancing drug in endurance athletes.
| Storage: | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
| Reconstitution: | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
| Swiss-Prot: | P01588 |
 | Recombinant Human Erythropoietin/EPO Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 60-65kDa. |
 | The purity of Human EPO/MVCD2 Protein was greater than 95% as determined by SEC- HPLC. |
Related Products
